A biomarker which importance is clearly increasing, is the tumour mutational burden (TMB; number of somatic mutations per megabase [mut/Mb]). Furthermore, there has been some research into the role of plasma-based TMB as a biomarker, although this has been done only in anti-PD-L1 therapy studies or in combination therapy with PD-L1/cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blockade. Aggarwal et al. investigated whether pTMB can be used as a predictive biomarker in chemoimmunotherapy.
The researchers used a cohort which consisted of 66 treatment-naïve patients with stage IV non-squamous NSCLC without EGFR/ALK/ROS1/BRAF-mutations. Patients were randomised to pembrolizumab monotherapy (n=31) and pembrolizumab + chemotherapy (n=36). At 9 weeks, pTMB was compared to Response Evaluation Criteria in Solid Tumors (RECIST) response and 6 months durable clinical benefit. High and low pTMB were defined at a cut-off of 16 mut/Mb .
The results show...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Influence of age on disease progression Next Article
Tool to measure quality of life in MS »
Table of Contents: WCLC 2019
Screening, Detection, and Diagnosis
Non-Small-Cell Lung Cancer
Other Thoracic Malignancies
Phase 3 Trial Updates
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.